Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine - PubMed (original) (raw)
Clinical Trial
. 2004 Mar 11;350(11):1104-10.
doi: 10.1056/NEJMoa030505.
Affiliations
- PMID: 15014183
- DOI: 10.1056/NEJMoa030505
Free article
Clinical Trial
Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine
Jes Olesen et al. N Engl J Med. 2004.
Free article
Abstract
Background: Calcitonin gene-related peptide (CGRP) may have a causative role in migraine. We therefore hypothesized that a CGRP-receptor antagonist might be effective in the treatment of migraine attacks.
Methods: In an international, multicenter, double-blind, randomized clinical trial of BIBN 4096 BS, a highly specific and potent nonpeptide CGRP-receptor antagonist, 126 patients with migraine received one of the following: placebo or 0.25, 0.5, 1, 2.5, 5, or 10 mg of BIBN 4096 BS intravenously over a period of 10 minutes. A group-sequential adaptive treatment-assignment design was used to minimize the number of patients exposed.
Results: The 2.5-mg dose was selected, with a response rate of 66 percent, as compared with 27 percent for placebo (P=0.001). The BIBN 4096 BS group as a whole had a response rate of 60 percent. Significant superiority over placebo was also observed with respect to most secondary end points: the pain-free rate at 2 hours; the rate of sustained response over a period of 24 hours; the rate of recurrence of headache; improvement in nausea, photophobia, phonophobia, and functional capacity; and the time to meaningful relief. An effect was apparent after 30 minutes and increased over the next few hours. The overall rate of adverse events was 25 percent after the 2.5-mg dose of the drug and 20 percent for the BIBN 4096 BS group as a whole, as compared with 12 percent for placebo. The most frequent side effect was paresthesia. There were no serious adverse events.
Conclusions: The CGRP antagonist BIBN 4096 BS was effective in treating acute attacks of migraine.
Copyright 2004 Massachusetts Medical Society
Comment in
- CGRP-receptor antagonists--a fresh approach to migraine therapy?
Durham PL. Durham PL. N Engl J Med. 2004 Mar 11;350(11):1073-5. doi: 10.1056/NEJMp048016. N Engl J Med. 2004. PMID: 15014178 No abstract available. - New drugs for the prevention and treatment of migraine: topiramate and BIBN 4096 BS.
Doggrell SA. Doggrell SA. Expert Opin Pharmacother. 2004 Aug;5(8):1837-40. doi: 10.1517/14656566.5.8.1837. Expert Opin Pharmacother. 2004. PMID: 15264998
Similar articles
- Modelling the anti-migraine effects of BIBN 4096 BS: a new calcitonin gene-related peptide receptor antagonist.
Trocóniz IF, Wolters JM, Tillmann C, Schaefer HG, Roth W. Trocóniz IF, et al. Clin Pharmacokinet. 2006;45(7):715-28. doi: 10.2165/00003088-200645070-00006. Clin Pharmacokinet. 2006. PMID: 16802852 Clinical Trial. - [Innovative treatment of acute migraine pain with CGRP receptor antagonists].
Herbert MK, Holzer P. Herbert MK, et al. Anasthesiol Intensivmed Notfallmed Schmerzther. 2004 Nov;39(11):657-61. doi: 10.1055/s-2004-826037. Anasthesiol Intensivmed Notfallmed Schmerzther. 2004. PMID: 15523578 Review. German. - Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine.
Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ. Lipton RB, et al. N Engl J Med. 2019 Jul 11;381(2):142-149. doi: 10.1056/NEJMoa1811090. N Engl J Med. 2019. PMID: 31291516 Clinical Trial. - Clinical and preclinical rationale for CGRP-receptor antagonists in the treatment of migraine.
Tepper SJ, Stillman MJ. Tepper SJ, et al. Headache. 2008 Sep;48(8):1259-68. doi: 10.1111/j.1526-4610.2008.01214.x. Headache. 2008. PMID: 18808506 Review.
Cited by
- Development of anti-migraine therapeutics using the capsaicin-induced dermal blood flow model.
Buntinx L, Vermeersch S, de Hoon J. Buntinx L, et al. Br J Clin Pharmacol. 2015 Nov;80(5):992-1000. doi: 10.1111/bcp.12704. Epub 2015 Oct 6. Br J Clin Pharmacol. 2015. PMID: 26114340 Free PMC article. Review. - Effect of CGRP and sumatriptan on the BOLD response in visual cortex.
Asghar MS, Hansen AE, Larsson HB, Olesen J, Ashina M. Asghar MS, et al. J Headache Pain. 2012 Mar;13(2):159-66. doi: 10.1007/s10194-011-0415-4. Epub 2012 Jan 14. J Headache Pain. 2012. PMID: 22246026 Free PMC article. Clinical Trial. - Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial.
Schwedt TJ, Myers Oakes TM, Martinez JM, Vargas BB, Pandey H, Pearlman EM, Richardson DR, Varnado OJ, Cobas Meyer M, Goadsby PJ. Schwedt TJ, et al. Neurol Ther. 2024 Feb;13(1):85-105. doi: 10.1007/s40120-023-00562-w. Epub 2023 Nov 10. Neurol Ther. 2024. PMID: 37948006 Free PMC article. - The evolving landscape and research trend of calcitonin gene-related peptide in migraine: A bibliometric analysis and visualization.
Wang L, Wang Q, Diao H, Liu X, Zhao Y. Wang L, et al. Front Neurol. 2024 Jun 24;15:1415760. doi: 10.3389/fneur.2024.1415760. eCollection 2024. Front Neurol. 2024. PMID: 38978815 Free PMC article. - Delayed upregulation of ATP P2X3 receptors of trigeminal sensory neurons by calcitonin gene-related peptide.
Fabbretti E, D'Arco M, Fabbro A, Simonetti M, Nistri A, Giniatullin R. Fabbretti E, et al. J Neurosci. 2006 Jun 7;26(23):6163-71. doi: 10.1523/JNEUROSCI.0647-06.2006. J Neurosci. 2006. PMID: 16763024 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials